In this latest edition of Journal Club, Jon Matthew Farber, MD, breaks down the value of physical examination in diagnosing rare conditions like spontaneous pneumomediastinum. Read the full case and thoughts from Dr. Farber here: hubs.li/Q03TkXLy0

New from the FDA: The agency accepts Arcutis Biotherapeutics' sNDA application for #roflumilast cream 0.3% (Zoryve) to treat #plaque #psoriasis in children aged 2 to 5 years. More details to come on hubs.li/Q03TwT6c0.

FULL DETAILS: contemporarypediatrics.com/view/fda-accep…

From our coverage of last month's Child Neurology Society Annual Meeting, Olivia Kim-McManus, MD, explains the excitement currently going on in the space. Get an idea of how the pediatric #neurology space is evolving: contemporarypediatrics.com/view/olivia-ki…

Rajani Aatra, MS, MSc, a licensed and certified #genetic counselor @mottchildren explains how early genetic testing is being recognized as an important tool for improving long-term outcomes in children at risk for inherited connective tissue disorders. hubs.ly/Q03T_cLZ0

Alice Hoyt MD, FAAAI, discussed the Early Childhood #Anaphylaxis Collaborative’s efforts to improve anaphylaxis preparedness in early childcare settings. Watch the full interview and learn more about this collaborative, here: contemporarypediatrics.com/view/alice-hoy…

In our latest article, Herbert Bravo MD, Dan Feiten MD, and Andrew Cagle, MD, explain the changing type 1 #diabetes landscape from early identification to clinical implications. READ MORE: hubs.li/Q03Vh8TP0

Get caught up with Contemporary Pediatrics! In our Weekly Review, take a look at some of our top stories from last week (Monday, November 17, to Friday, November 21, 2025), and click on each link to read and watch anything you may have missed. hubs.li/Q03VwYmR0

Today, the #FDA granted 510(k) clearance to CeriBell Inc.'s AI-powered point-of-care Clarity algorithm to detect electrographic #seizures in #newborns. DETAILS: hubs.ly/Q03VFqk80

In our latest #puzzler quiz, try to diagnose this 8-year-old girl with a corneal lesion. View some case details below, then click the link for more information and to make your diagnosis. Can you diagnose this patient? View more: contemporarypediatrics.com/view/can-you-d…

In this clip, Jonathan Flyer, MD, division chief of Pediatric Cardiology at the University of Vermont Health Network for speaking with us about the recent launch of the LEAD initiative to increase pediatric #lipid screenings. Watch the full interview here:contemporarypediatrics.com/view/jonathan-…

ICYMI from the #FDA: Itvisma (onasemnogene abeparvovec-brve; Novartis) for children aged 2 years and older, adolescents, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in SMN1, is now approved. Full details: hubs.li/Q03VPkkX0

More #FDA news: Otsuka Pharmaceutical has submitted a new drug application for its investigational #ADHD treatment centanafadine for children, adolescents, and adults. More details: hubs.li/Q03VQ3Hj0

In this interview, Druhan Howell, MD, of Pulmonary Associates of Mobile and Organon Health Partner, discussed the safety and tolerability of #tapinarof cream 1% to treat pediatric #atopicdermatitis. Watch the full interview on tapinarof cream 1% here: contemporarypediatrics.com/view/druhan-ho…

A prepandemic NHANES analysis found no significant differences in fruit, vegetable, or overall diet quality between WIC participants and eligible nonparticipants. FULL DETAILS: hubs.li/Q03VZvWZ0

We’re grateful for the pediatricians, specialists, nurses, and families working together to support child health and wellbeing. 🦃🧸 Happy Thanksgiving from Contemporary Pediatrics — we hope your holiday is happy, healthy, and heart-warming.

If you missed it this week, Otsuka Pharmaceuticals, Inc. has submitted a new drug application for its investigational hashtag#ADHD treatment centanafadine for children, adolescents, and adults. More details: hubs.li/Q03VZHmD0

In this Q&A interview, Jonathan Strober, MD, explains recent long-term data from the Vibrance-MG Phase 2/3 LTE pediatric study of nipocalimab-aahu (IMAAVY) plus standard of care in pediatric patients with gMG. MORE: hubs.li/Q03VZKHt0